High Growth Tech Stocks to Watch in January 2025

The United States market has experienced a flat performance over the past week, but it is up 24% over the past year with earnings anticipated to grow by 15% annually in the coming years. In such an environment, identifying high growth tech stocks that can capitalize on these favorable conditions involves looking for companies with strong innovation and potential to sustain robust revenue expansion.

Top 10 High Growth Tech Companies In The United States

Name	Revenue Growth	Earnings Growth	Growth Rating
Super Micro Computer	24.13%	24.28%	★★★★★★
Ardelyx	22.86%	54.70%	★★★★★★
Alkami Technology	21.99%	102.65%	★★★★★★
AsiaFIN Holdings	51.75%	82.69%	★★★★★★
Clene	61.16%	59.11%	★★★★★★
Alnylam Pharmaceuticals	21.23%	56.37%	★★★★★★
TG Therapeutics	29.99%	44.07%	★★★★★★
Travere Therapeutics	28.68%	62.50%	★★★★★★
Seagen	22.57%	71.80%	★★★★★★
ImmunoGen	26.00%	45.85%	★★★★★★

Click here to see the full list of 235 stocks from our US High Growth Tech and AI Stocks screener.

Here's a peek at a few of the choices from the screener.

Advanced Energy Industries (NasdaqGS:AEIS)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Advanced Energy Industries, Inc. offers precision power conversion, measurement, and control solutions globally, with a market cap of approximately $4.57 billion.

Operations: The company generates its revenue primarily from Power Electronics Conversion Products, amounting to $1.47 billion.

Advanced Energy Industries (AEIS) is navigating a challenging landscape with its recent financial performance reflecting a significant one-off loss of $49.5M, impacting its results up to September 2024. Despite this setback, the company's strategic moves are noteworthy; it announced a quarterly dividend and is actively pursuing acquisitions to bolster future growth. AEIS's commitment to innovation is evident in its R&D spending trends, crucial for maintaining competitiveness in the tech sector. The firm's focus on expanding through acquisitions alongside organic growth initiatives like new product launches and market expansions suggests resilience and adaptability in a fluctuating market environment.

• Take a closer look at Advanced Energy Industries' potential here in our health report.

• Evaluate Advanced Energy Industries' historical performance by accessing our past performance report.

Cognex (NasdaqGS:CGNX)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Cognex Corporation develops machine vision products designed to capture and analyze visual information for automating manufacturing and distribution processes globally, with a market cap of approximately $6.28 billion.

Operations: Cognex Corporation generates revenue primarily from its machine vision technology, amounting to $881.50 million.

Cognex has demonstrated robust growth, with a notable increase in Q3 sales to $234.74 million from $197.24 million the previous year, and a rise in net income to $29.59 million from $18.92 million. This performance is underpinned by strategic expansions in logistics and semi sectors, despite a forecasted dip in Q4 revenue due to seasonal adjustments and operational recalibrations. The firm's commitment to shareholder returns is evident through an increased quarterly dividend and the repurchase of 82,000 shares for $3.97 million within the quarter, reflecting confidence in its financial health and future prospects.

• Delve into the full analysis health report here for a deeper understanding of Cognex.

• Gain insights into Cognex's historical performance by reviewing our past performance report.

SpringWorks Therapeutics (NasdaqGS:SWTX)

Simply Wall St Growth Rating: ★★★★★☆

Overview: SpringWorks Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing medicines for underserved patient populations with rare diseases and cancer, with a market cap of $2.89 billion.

Operations: SpringWorks Therapeutics focuses on developing and commercializing treatments for rare diseases and cancer, targeting underserved patient populations. The company operates as a commercial-stage biopharmaceutical entity with a market capitalization of approximately $2.89 billion.

SpringWorks Therapeutics, despite being unprofitable, is on a promising trajectory with an expected annual revenue growth of 37%, outpacing the U.S. market average of 9.1%. This growth is bolstered by significant developments in their clinical programs, notably the ReNeu trial for neurofibromatosis which reported a positive objective response rate and was well-received at recent healthcare conferences. Their commitment to innovation is evident as they navigate towards profitability within three years, reflecting a potential shift in their financial landscape and contributing positively to the biotech sector's evolution.

• Click to explore a detailed breakdown of our findings in SpringWorks Therapeutics' health report.

• Explore historical data to track SpringWorks Therapeutics' performance over time in our Past section.

Where To Now?

• Explore the 235 names from our US High Growth Tech and AI Stocks screener here.
• Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes.
• Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage.

Interested In Other Possibilities?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com